Ciloa, a French bioengineering company specializing in extracellular vesicles, has secured €6.5 million (US$7 million) in funding through the France 2030 initiative.

This funding, awarded via the “Biotherapies and Biomanufacturing of Innovative Therapies” program managed by Bpifrance, will support the clinical development and large-scale production of Ciloa’s therapeutic candidate, APN-sEV, for type 2 diabetes and obesity.

The funding will allow Ciloa to conduct regulatory preclinical trials for APN-sEV and initiate clinical trials.

Phase I trials are expected to begin in 2027, followed by Phase IIa in 2028.

The company plans to produce the treatment following Good Manufacturing Practices (GMP) to ensure safety and quality.

🔗 Source: Ciloa

🧠 Food for thought

1️⃣ Adiponectin’s therapeutic potential has been locked away for decades

Adiponectin has been recognized by researchers as a metabolic “guardian angel” for over 20 years, but therapeutic applications have been limited by production challenges.

This hormone exists naturally in human plasma at high concentrations (2-30 μg/ml) and has powerful insulin-sensitizing, anti-inflammatory, and cardioprotective properties that make it an attractive therapeutic target 1.

Low adiponectin levels are directly linked to metabolic syndrome, type 2 diabetes, and cardiovascular diseases, suggesting supplementation could address multiple conditions simultaneously 1.

Previous attempts to develop adiponectin-based therapies have struggled because the hormone exists in multiple forms (trimers, hexamers, and high-molecular weight multimers), with the latter being most biologically active but hardest to stabilize 1.

Ciloa’s approach of combining adiponectin with small extracellular vesicles represents a potential solution to the long-standing challenge of creating stable, functional adiponectin formulations, which has been a significant hurdle for researchers.

2️⃣ Exosome therapeutics are emerging as a next-generation drug delivery platform

Exosomes represent a rapidly developing field in drug delivery with $7.6M in funding for Ciloa being part of a broader investment trend in this technology.

These naturally occurring nano-sized vesicles (30-100 nm) are increasingly valued for their ability to cross biological barriers and deliver therapeutic payloads to specific tissues 2.